Remove

Under the Paperwork Reduction Act of 1995, no persons are required to resp

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10710747				
	Filing Date		2004-07-30				
	First Named Inventor	TAK	TAKESHI OI				
	Art Unit		3611				
	Examiner Name	Mark	on A. Arce Diaz				
	Attorney Docket Number		SIC-04-011				

	U.S.PATENTS			Remove							
Examiner Cite Patent Number Kind Code1		Issue E	Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevar Figures Appear					
	1	4678054	A	1987-0	7-07	Honda et al.					
	2	5478100	78100 A 1995-12-26 McDermitt, Jr. et al.								
	3	6695335	B1	2004-0	2-24	Gaastra					
If you wisi	If you wish to add additional U.S. Patent citation information please click the Add button. Add										
			U.S.P	ATENT	APPLIC	CATION PUBL	LICATIONS		Remove		
		Name of Pate of cited Docu	entee or Applicant iment	Releva		Lines when ges or Relev					
	1										
If you wisl	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	olease click the Ad	d button	Add		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²			Publication Date	Name of Patente Applicant of cited Document	e or	where Rel	or Relevant	тя
	1	19712326	DE		A1	1998-10-01	Schauff				

II S PATENTS

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Tagminer Name Art Unit Art Unit

Application Number		10710747		
Filing Date		2004-07-30		
First Named Inventor TAKE		SHI OI		
Art Unit		3611		
Examiner Name Mark		on A. Arce Diaz		
Attorney Docket Number		SIC-04-011		

Date Considered

	2	9941138	wo	A1	1999-08-19	Clarkson			
If you wish to add additional Foreign Patent Document citation information please click the Add button Add									
NON-PATENT LITERATURE DOCUMENTS Remove							Remove		
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city andoric country where published.							T6	
	1 EP Search Report for EP 04018275.0, the European patent application which corresponds to this application, dated January 18, 2006.								
If you wis	If you wish to add additional non-patent literature document citation information please click the Add button Add								
			EX	AMINE	R SIGNATUR	E			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Codes of USPTO Patent Documents at view (LISPTO_GDV or MRPP 96104. Finter office that issued the document, by the Noveleton (WIPO Standard ST3.) First planeses patent document, the archaestor of the parent or the representation process to see and respect of the parent or parent parent or

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10710747
Filing Date		2004-07-30
First Named Inventor	TAKE	SHI OI
Art Unit		3611
Examiner Name	Mark	n A. Arce Diaz
Attorney Docket Number		SIC-04-011

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and	1.98 to make the appropriate selection(s):	
----------------------------	--	--

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 1.97(eVI.1)

OR

That no item of information contained in the information disclosure statement, was cited in a communication from a foreign parter office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(c)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- □ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/James A. Deland/	Date (YYYY-MM-DD)	2006-05-22
Name/Drint	Ismae A Daland	Registration Number	31242

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is folling fairly the USFPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USFPT. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, U.S. Operatment of Commence, P. 0. Bot 1450, Alexandria, V.3231-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. 0. Box 1450, Alexandria, V.2231-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.